PerkinElmer Inc Stock News

PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

PerkinElmer, Inc. (NYSE:PKI ) Baird's 2022 Global Healthcare Conference September 13, 2022 10:50 AM ET Company Participants Prahlad Singh - CEO Conference Call Participants Tom Peterson - Baird Tom Pe

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

Analysts have provided the following ratings for PerkinElmer (NYSE:PKI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 5 2 0 Last 3

PerkinElmer has sold a substantial business in recent times, in order to fully focus on life science and diagnostic activities. The deal looks a bit cheap but is likely okay in the long run.

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

You've probably never heard of them, but they're both winners.

You've probably never heard of them, but they're both winners.

Upgrades According to Goldman Sachs, the prior rating for FREYR Battery (NYSE:FREY) was changed from Neutral to Buy. In the second quarter, FREYR Battery showed an EPS of $0.24, compared to $0.04 from

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 2022 Wells Fargo Heal

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.